CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 51 enrolled
Drug / intervention
Ribavirin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00500578
NCT00500578Phase 4Completed
CompareCT.gov

A Randomized Study Evaluating Two Different Schedules of Aerosolized Ribavirin For Treatment of RSV Upper Respiratory Infections in Patients With Hematological Malignancies

M.D. Anderson Cancer Center·interventional·Posted Jul 12, 2007·Updated Aug 1, 2012

In Brief

A Phase 4 clinical trial evaluating Ribavirin for Hematological Malignancies. Completed, enrolled 51 participants across 1 site.

Detailed Summary

Primary Objectives: 1. To determine whether aerosolized ribavirin is effective when given at an intermittent dose over 3 hours every 8 hours for therapy of RSV upper respiratory tract infection (URI) and whether it can prevent progression to pneumonia. 2. To determine the effect of this regimen on persistence of viral shedding.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematological Malignancies
CountriesUnited States
CollaboratorsICN Pharmaceuticals

Timeline

Phase 4CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 12, 2007
Enrollment StartFeb 1, 2003
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 19.0 years ago

Interventions

Ribavirindrug

Arm 1 = 6 Grams Over 18 hours Every 24 Hours

Ribavirindrug

Arm 2 = 2 Grams Over 3 Hours Every 8 Hours.